Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition-Reference-Cited by-同舟云学术

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

Published:2004-11-14 Issue:12 Volume:11 Page:1192-1197
ISSN:1545-9993
Container-title:Nature Structural & Molecular Biology
language:en
Short-container-title:Nat Struct Mol Biol

Author:

Ohren Jeffrey F,Chen Huifen,Pavlovsky Alexander,Whitehead Christopher,Zhang Erli,Kuffa Peter,Yan Chunhong,McConnell Patrick,Spessard Cindy,Banotai Craig,Mueller W Thomas,Delaney Amy,Omer Charles,Sebolt-Leopold Judith,Dudley David T,Leung Iris K,Flamme Cathlin,Warmus Joseph,Kaufman Michael,Barrett Stephen,Tecle Haile,Hasemann Charles A

Publisher

Springer Science and Business Media LLC

Subject

Molecular Biology,Structural Biology

Link

http://www.nature.com/articles/nsmb859.pdf

Reference40 articles.

1. Ahn, N.G. et al. Multiple components in an epidermal growth factor–stimulated protein kinase cascade: in vitro activation of a myelin basic protein/microtubule-associated protein 2 kinase. J. Biol. Chem. 266, 4220–4227 (1991).

2. Zheng, C-F. & Guan, K. Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2. J. Biol. Chem. 268, 11435–11439 (1993).

3. Dhanasekaran, N. & Reddy, P. Signaling by dual-specificity kinases. Oncogene 17, 1447–1455 (1998).

4. Kolch, W. Ras/Raf signaling and emerging pharmacotherapeutic targets. Expert Opin. Pharmacother. 3, 709–718 (2002).

5. Schaeffer, H.J. & Weber, M.J. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol. Cell. Biol. 19, 2435–2444 (1999).

Cited by 556 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conserved gatekeeper methionine regulates the binding and access of kinase inhibitors to ATP sites of MAP2K1, 4, and 7: Clues for developing selective inhibitors;Bioorganic & Medicinal Chemistry Letters;2024-11

2. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

3. Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature;Drugs in R&D;2024-08-23

4. Effector Binding Sequentially Alters KRAS Dimerization on the Membrane: New Insights Into RAS‐Mediated RAF Activation;Advanced Science;2024-08-13

5. Scalable and universal prediction of cellular phenotypes;2024-08-12